376 related articles for article (PubMed ID: 21862455)
1. Elevated N-terminal pro-brain natriuretic peptide levels predict an enhanced anti-hypertensive and anti-proteinuric benefit of dietary sodium restriction and diuretics, but not angiotensin receptor blockade, in proteinuric renal patients.
Slagman MC; Waanders F; Vogt L; Damman K; Hemmelder M; Navis G; Laverman GD
Nephrol Dial Transplant; 2012 Mar; 27(3):983-90. PubMed ID: 21862455
[TBL] [Abstract][Full Text] [Related]
2. Effect of renin-angiotensin-aldosterone system inhibition, dietary sodium restriction, and/or diuretics on urinary kidney injury molecule 1 excretion in nondiabetic proteinuric kidney disease: a post hoc analysis of a randomized controlled trial.
Waanders F; Vaidya VS; van Goor H; Leuvenink H; Damman K; Hamming I; Bonventre JV; Vogt L; Navis G
Am J Kidney Dis; 2009 Jan; 53(1):16-25. PubMed ID: 18823687
[TBL] [Abstract][Full Text] [Related]
3. Fibroblast growth factor 23 and the antiproteinuric response to dietary sodium restriction during renin-angiotensin-aldosterone system blockade.
Humalda JK; Lambers Heerspink HJ; Kwakernaak AJ; Slagman MC; Waanders F; Vervloet MG; Ter Wee PM; Navis G; de Borst MH;
Am J Kidney Dis; 2015 Feb; 65(2):259-66. PubMed ID: 25278093
[TBL] [Abstract][Full Text] [Related]
4. Vascular endothelial growth factor C levels are modulated by dietary salt intake in proteinuric chronic kidney disease patients and in healthy subjects.
Slagman MC; Kwakernaak AJ; Yazdani S; Laverman GD; van den Born J; Titze J; Navis G
Nephrol Dial Transplant; 2012 Mar; 27(3):978-82. PubMed ID: 21778278
[TBL] [Abstract][Full Text] [Related]
5. Triple pharmacological blockade of the renin-angiotensin-aldosterone system in nondiabetic CKD: an open-label crossover randomized controlled trial.
Tylicki L; Rutkowski P; Renke M; Larczyński W; Aleksandrowicz E; Lysiak-Szydlowska W; Rutkowski B
Am J Kidney Dis; 2008 Sep; 52(3):486-93. PubMed ID: 18423812
[TBL] [Abstract][Full Text] [Related]
6. Diuretic uptitration with half dose combined ACEI + ARB better decreases proteinuria than combined ACEI + ARB uptitration.
Esnault VL; Ekhlas A; Nguyen JM; Moranne O
Nephrol Dial Transplant; 2010 Jul; 25(7):2218-24. PubMed ID: 20106824
[TBL] [Abstract][Full Text] [Related]
7. Benefits of dietary sodium restriction in the management of chronic kidney disease.
Krikken JA; Laverman GD; Navis G
Curr Opin Nephrol Hypertens; 2009 Nov; 18(6):531-8. PubMed ID: 19713840
[TBL] [Abstract][Full Text] [Related]
8. Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker.
Furumatsu Y; Nagasawa Y; Tomida K; Mikami S; Kaneko T; Okada N; Tsubakihara Y; Imai E; Shoji T
Hypertens Res; 2008 Jan; 31(1):59-67. PubMed ID: 18360019
[TBL] [Abstract][Full Text] [Related]
9. Erythropoietin is reduced by combination of diuretic therapy and RAAS blockade in proteinuric renal patients with preserved renal function.
Slagman MC; Sinkeler SJ; Hemmelder MH; Waanders F; Vogt L; Kluin-Nelemans HC; Navis G; Laverman GD
Nephrol Dial Transplant; 2010 Oct; 25(10):3256-60. PubMed ID: 20339099
[TBL] [Abstract][Full Text] [Related]
10. Sodium restriction on top of renin-angiotensin-aldosterone system blockade increases circulating levels of N-acetyl-seryl-aspartyl-lysyl-proline in chronic kidney disease patients.
Kwakernaak AJ; Waanders F; Slagman MC; Dokter MM; Laverman GD; de Boer RA; Navis G
J Hypertens; 2013 Dec; 31(12):2425-32. PubMed ID: 24029871
[TBL] [Abstract][Full Text] [Related]
11. Angiotensin receptor blockade and exercise capacity in adults with systemic right ventricles: a multicenter, randomized, placebo-controlled clinical trial.
Dore A; Houde C; Chan KL; Ducharme A; Khairy P; Juneau M; Marcotte F; Mercier LA
Circulation; 2005 Oct; 112(16):2411-6. PubMed ID: 16216961
[TBL] [Abstract][Full Text] [Related]
12. Interim evidence of the renoprotective effect of the angiotensin II receptor antagonist losartan versus the calcium channel blocker amlodipine in patients with chronic kidney disease and hypertension: a report of the Japanese Losartan Therapy Intended for Global Renal Protection in Hypertensive Patients (JLIGHT) Study.
Iino Y; Hayashi M; Kawamura T; Shiigai T; Tomino Y; Yamada K; Kitajima T; Ideura T; Koyama A; Sugisaki T; Suzuki H; Umemura S; Kawaguchi Y; Uchida S; Kuwahara M; Yamazaki T;
Clin Exp Nephrol; 2003 Sep; 7(3):221-30. PubMed ID: 14586719
[TBL] [Abstract][Full Text] [Related]
13. Effects of dietary sodium and hydrochlorothiazide on the antiproteinuric efficacy of losartan.
Vogt L; Waanders F; Boomsma F; de Zeeuw D; Navis G
J Am Soc Nephrol; 2008 May; 19(5):999-1007. PubMed ID: 18272844
[TBL] [Abstract][Full Text] [Related]
14. Blockade of renin-angiotensin-aldosterone system in kidney and heart disease: how much do we need?
Lim S
Acta Med Indones; 2008 Jan; 40(1):34-7. PubMed ID: 19054878
[TBL] [Abstract][Full Text] [Related]
15. Effect of pentoxifylline on proteinuria, markers of tubular injury and oxidative stress in non-diabetic patients with chronic kidney disease - placebo controlled, randomized, cross-over study.
Renke M; Tylicki L; Rutkowski P; Knap N; Zietkiewicz M; Neuwelt A; Aleksandrowicz E; Łysiak-Szydłowska W; Woźniak M; Rutkowski B
Acta Biochim Pol; 2010; 57(1):119-23. PubMed ID: 20309434
[TBL] [Abstract][Full Text] [Related]
16. Effects of sodium restriction and hydrochlorothiazide on RAAS blockade efficacy in diabetic nephropathy: a randomised clinical trial.
Kwakernaak AJ; Krikken JA; Binnenmars SH; Visser FW; Hemmelder MH; Woittiez AJ; Groen H; Laverman GD; Navis G;
Lancet Diabetes Endocrinol; 2014 May; 2(5):385-95. PubMed ID: 24795252
[TBL] [Abstract][Full Text] [Related]
17. Renoprotective RAAS inhibition does not affect the association between worse renal function and higher plasma aldosterone levels.
Gant CM; Laverman GD; Vogt L; Slagman MCJ; Heerspink HJL; Waanders F; Hemmelder MH; Navis G;
BMC Nephrol; 2017 Dec; 18(1):370. PubMed ID: 29262813
[TBL] [Abstract][Full Text] [Related]
18. Intravenous iron reduces NT-pro-brain natriuretic peptide in anemic patients with chronic heart failure and renal insufficiency.
Toblli JE; Lombraña A; Duarte P; Di Gennaro F
J Am Coll Cardiol; 2007 Oct; 50(17):1657-65. PubMed ID: 17950147
[TBL] [Abstract][Full Text] [Related]
19. [Antiproteinuric effect of renin-angiotensin system blockade in patients with normal/lower than 115 mmHg systolic blood pressure].
Gutiérrez E; González E; Morales E; Herrero JC; Manzanera MJ; García JA; Domínguez-Gil B; Hernández E; Praga M
Nefrologia; 2004; 24(6):546-52. PubMed ID: 15683026
[TBL] [Abstract][Full Text] [Related]
20. Renin angiotensin system blockade and cardiovascular outcomes in patients with chronic kidney disease and proteinuria: a meta-analysis.
Balamuthusamy S; Srinivasan L; Verma M; Adigopula S; Jalandhara N; Hathiwala S; Smith E
Am Heart J; 2008 May; 155(5):791-805. PubMed ID: 18440325
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
